Denemek ALTIN - Özgür

Revitalising Cosmetic Standards & Compliance

Bio Spectrum

|

October 2025

A huge craze among consumers for cosmeceuticals, by going into marketing and brand appeal, is setting a dangerous precedent.

- Sanjiv Das

Above all, fake cosmetic products have flooded the Indian market, which are easily available online and across street markets. Keeping this in mind and to stop unscrupulous ads, the Ministry of Health and Family Welfare has officially published the Cosmetics (Amendment) Rules, 2025, which introduce a series of changes to the existing Cosmetics Rules, 2020. Experts weigh in on how this Act can be a game-changer in the cosmeceutical sector, provided strict norms are followed. Stacks of cosmetics at medical and departmental stores remind us of the easy availability of the products.

Not realising what best suits the skin, hair etc, without a proper doctor's prescription, consumers are on a buying frenzy, inclined to the marketing and brand appeal rather than thoroughly analysing product details such as ingredients or proper skin type alignment etc.

The cosmeceutical industry is an ever-growing sector backed by consumer awareness, disposable income, a preferential shift towards various products. According to the India Brand Equity Foundation, a trust established by the Department of Commerce, Ministry of Commerce and Industry, Government of India, the cosmeceuticals market generated an estimated revenue of $1.645 billion in 2024 and is projected to reach around $2.27 billion by 2030, growing at a CAGR of approximately 5.4 per cent from 2025 to 2030.

Players in the field are in a rat race to gain consumer preference. Backed by e-commerce and social media platforms, there is no backing out for this growing sector. From bigger pharma giants to smaller players, everyone wants to join the bandwagon. And these are easily available across e-commerce platforms. With products also available on street markets, sometimes having no expiry dates mentioned or a fake one, without proper labelling, is a matter of worry that can lead to serious side effects.

Confiscation of fake cosmetics

Bio Spectrum'den DAHA FAZLA HİKAYE

Bio Spectrum

Bio Spectrum

IASST synthesises new compound to combat aggressive breast cancer

A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.

time to read

1 min

October 2025

Bio Spectrum

DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

WHO unveils updated guideline on HIV service delivery

WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.

time to read

1 min

October 2025

Bio Spectrum

Scientists in Kolkata explore therapeutic potential of accessory proteins

A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

US FDA advances rare disease drug development

The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

time to read

1 min

October 2025

Bio Spectrum

WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

time to read

1 min

October 2025

Bio Spectrum

Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification

Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.

time to read

1 min

October 2025

Bio Spectrum

Aodh Lifesciences gets support from TDB to redefine pneumonia treatment

The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

Antara Senior Care names Mukesh Ghuraiya as Chief Marketing Officer

Antara Senior Care, a fully integrated senior care ecosystem, has appointed Mukesh Ghuraiya as the Executive Vice-President and Chief Marketing Officer (CMO).

time to read

1 min

October 2025

Bio Spectrum

Poly Medicure acquires PendraCare Group for Rs 188.5 Cr

Poly Medicure, a Delhi-based medical device company, has announced signing of definitive agreements to acquire 90 per cent stake in PendraCare Group consisting of PendraCare Holdings and Welling Medical from Welling Holdings B.V. at an Enterprise value of Rs 188.5 crore (Euro 18.3 million).

time to read

1 min

October 2025

Listen

Translate

Share

-
+

Change font size